CHCWM – Cancer & Hematology Centers of West Michigan

JTX 8064 (Jounce, Inc)

Description:  Phase 1 First-in-Human Study of Leukocyte Immunoglobulin-Like Receptor B2 Inhibitor Monoclonal Antibody JTX-8064, as Monotherapy & in Combination with a Programmed Cell Death Receptor-1 Inhibitor, in Adult Subjects with Advanced Refractory Solid Tumor Malignancies

Mechanism of Action:  JTX 8064 (mAB to LILRB2-myeloid checkpoint) with or without PD1 inhibitor

Target Patient Population:  Expansion cohorts Head & Neck, Ovarian, Clear Cell RCC, and cutaneous squamous cell carcinomas..

Study Design:  Drug is given IV every 3 weeks.